ReviewWorld journal of gastroenterology2010
Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how?
Review in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Ten-year follow-up of endoscopic mucosal resection versus esophagectomy for esophageal intramucosal adenocarcinoma in the setting of Barrett's esophagus: a Canadian experience.Surgical endoscopy · 2023Article
- Detection of Second Primary Malignancies of the Esophagus and Hypophraynx in Oral Squamous Cell Carcinoma Patients.Laryngoscope investigative otolaryngology · 2018Article
- Interventional Therapy of Esophageal Cancer.Gastrointestinal tumors · 2016Review
- Endoscopic resection of gastric and esophageal cancer.Gastroenterology report · 2015Review
- Minimally invasive esophagectomy for dysplastic Barrett's esophagus.World journal of surgery · 2015Review
- Endoscopic methods in the treatment of early-stage esophageal cancer.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2014Review
- Low risk of prevalent submucosal invasive cancer among patients undergoing esophagectomy for treatment of Barrett's esophagus with high grade dysplasia.Journal of gastrointestinal oncology · 2011Article
- Optimal management of Barrett's esophagus: pharmacologic, endoscopic, and surgical interventions.Therapeutics and clinical risk management · 2011Article
- Gastroesophageal reflux disease: From heartburn to cancer.World journal of gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade dysplasia (HGD) and intramucosal carcinoma (IMC) in the setting of Barrett's esophagus have traditionally been treated with esophagectomy. However, with the advent of endoscopic mucosal resection and endoscopic ablative therapies, endoscopic therapy at centers with expertise is now an established treatment of Barrett's-esophagus-related neoplasia, including HGD and IMC. Esophagectomy is today reserved for more selected cases with submucosal invasion, evidence for lymph node metastasis, or unsuccessful endoscopic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.